PACIRA BIOSCIENCES INC (PCRX)

US6951271005 - Common Stock

20.03  +0.05 (+0.25%)

After market: 20.03 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (7/26/2024, 3:10:08 PM)

After market: 20.03 0 (0%)

20.03

+0.05 (+0.25%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-37.66%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap932.40M
Shares
PE6.65
Fwd PE5.48
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PCRX Daily chart

Company Profile

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 711 full-time employees. The company went IPO on 2011-02-03. The firm's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. The company is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Company Info

PACIRA BIOSCIENCES INC

5401 West Kennedy Boulevard, Suite 890

Tampa FLORIDA 07054

P: 18135536680

CEO: David Stack

Employees: 711

Website: https://www.pacira.com/

PCRX News

News Image2 days ago - Market News VideoFirst Week of September 20th Options Trading For Pacira BioSciences (PCRX)
News Image3 days ago - Pacira BioSciencesPacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
News Image7 days ago - Market News VideoNoteworthy Friday Option Activity: OPK, ABR, PCRX
ChartMill News Image9 days ago - ChartmillIn a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is probably undervalued for the fundamentals it is displaying.

News Image16 days ago - Pacira BioSciencesCenters for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
News Image16 days ago - Pacira BioSciencesCenters for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical...

PCRX Twits

Here you can normally see the latest stock twits on PCRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example